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requires us to select the right tool or tools
for each particular job. Thus, much as I
would choose a hammer to drive a nail
into place, I would include the use of con-
tact isolation in the management of a pa-
tient with infectious diarrhea or a draining
wound (hardly “exceptional cases”).
It is said that to a person with a ham-
mer, everything looks like a nail, and per-
haps this is even more true of someone
who consults for a hammer company.
When 2 experts in the field of health care
epidemiology repeatedly call for “every
health care facility” to implement a pro-
gram of active detection and isolation,
they rightfully attract our attention. When
one of these experts discloses potential
conflicts of interest that include a rela-
tionship with a company that markets a
diagnostic test for MRSA, we must view
these calls with caution.
A hammer, and even a wrench, might
drive a screw into a piece of board. In the
case of a screw, though, a better tool is
available. My paper was intended to help
hospitals consider conditions in which
isolation might be the most appropriate
tool for preventing health care–associated
infections. A similar approach to the rest
of the toolbox seems warranted.
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From Plasma BK Viral Load
to Allograft Damage:
Rule of Thumb
for Estimating the Intrarenal
Cytopathic Wear
To the Editor—The BK virus, which is a
member of the polyomavirus family, is the
etiologic agent of polyomavirus-associated
nephropathy, a disease affecting 10% of
kidney transplant recipients with irrevers-
ible loss of allograft function. With the in-
creased potency of new immunosuppres-
sive drugs, polyomavirus-associated
nephropathy has become an escalating
threat [1]. Under transplant immunosup-
pression, lytic replication of the BK virus
in kidney tubular epithelial cells drives the
course of polyomavirus-associated nephro-
pathy [2–4]. Removal of the kidney allo-
graft is associated with vanishing BK vire-
mia, usually within 1–2 weeks [3, 5].
Here we delineate how to estimate the
BK virus–mediated intrarenal cytopathic
wear directly from data on quantitative
plasma BK viral load. Our rule of thumb
proposes that a BK viral load of 1000 cop-
ies/mL corresponds to 1 lysed cell per day.
Hence, a BK viral load of 50,000 copies/
mL would result in a cytopathic wear of
∼ cells per individual per day51.25 10
(90% confidence interval, 50.31–5 10
cells per individual per day) (figure 1A).
The in vivo half-life of the BK virus after
removal of the source of viral replication
(ie, after nephrectomy) has been estimated
to be 1–2 h [3]. Thus, during a 24-h pe-
riod, a given viral load decreases 212–224-
fold (figure 1B). To maintain a dynamic
equilibrium state for 24 h, ongoing re-
placement of plasma virus is required,
with a replacement rate of ∼10 per day
(half-life, 1.5 h) [3]. Hence, the daily viral
turnover with replacement is ∼10 times a
detected viral load (≈1000%). During
phases of viral expansion or contraction,
a (stepwise) integration over the viral-load
changes would be required (figure 1C).
Data from patients who show histological
evidence of polyomavirus-associated ne-
phropathy indicate in situ a mean burst
size of ∼10,000 virions per infected host
cell (range, 3–44,000 virions per infected
host cell)—in line with recent in vitro ex-
periments yielding a somewhat higher in-
tracellular BK viral DNA load per cell [6–
9]. Division of the total viral turnover by
the burst size yields the number of host
cells liberating their viral progeny into
plasma; in this case, a BK viral load of
1000 copies/mL would correspond to 1
cell per day. Hence, plasma viral loads—
scaled to whole-body levels—serve as a
rough approximation of the daily intrare-
nal cytopathic wear associated with BK vi-
rus replication. For a packed cell volume
(hematocrit) of 0.5, the formula further
simplifies to X  2.5 p Y, where X de-
notes the detected plasma BK viral load
in copies/mL and Y denotes the daily cy-
topathic wear per individual (figure 1A;
see “one-step calculator”). If the plasma
BK viral loads represented 1% of the virus
produced in the allograft, then the true
cytopathic wear would be 100 times high-
er. Other percentages change this es-
timate proportionately. Note that, be-
cause cells infected with the BK virus live
on average 2–3 days before liberating
their viral progeny [4, 8, 9], at any time,
the infected cells exceed the lysed cells
by a factor of 2–3. The simple rule-
of-thumb approximation breaks down
when viral fluxes between distinct repli-
cation sites come into play. In such com-
plex systems, mathematical modeling still
allows one to disentangle the respective
cytopathic contributions [10].
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Figure 1. A, Structure of the rule of thumb, one-step calculator, and numerical example. The input
BK viral load is 50,000 copies/mL. The selected constants and/or parameter values are as follows: c, 10
per day (half-life, ∼1.5 h); b, 10,000 progeny viruses per host cell; blood volume, 5 L, packed cell volume
(hematocrit), 0.5. The BK viral loads, the clearance (replacement) rates, and the burst sizes (all derived
from the use of polymerase chain reaction) each have an error of 2, which yields a 90% probability
that our estimate deviates 4-fold and a 70% probability that it deviates 2-fold from the true value.
Note that replacing our selected constants by other (patient-specific) values affects the result in a linear
manner; however, the deviation probabilities do not change. B, Viral decay during a 24-h period plotted
on a log scale. The red line represents the decay curve for a viral half-life of 1.5 h; the black dashed
lines represent decay curves for viral half-lives of 1 and 2 h, respectively. The light blue area represents
the viral load to be replaced during a 24-h period, to maintain a dynamic equilibrium state. C, Cytopathic
wear, where TC denotes cellular turnover in a dynamic equilibrium state (left) or during viral expansion
(right). The correction term for expanding (or contracting) viral loads is given in the squared bracket. Its
derivation requires some calculus, where c is the viral replacement rate [1/day]; b is the viral burst size
per host cell [viruses/cell]; V1 and V2 are the detected viral loads [copies/mL]; t1 and t2 are the sampling
times [days]; and s is the slope of viral load change (sp [ln (V2)  ln (V1)]/(t2  t1)).
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